Cargando…
Protocol for a phase II, open-label exploratory study investigating the efficacy of fesoterodine for treatment of adult patients with spinal cord injury suffering from neurogenic detrusor overactivity for amelioration of autonomic dysreflexia
INTRODUCTION: Managing and preventing risk factors associated with cardiovascular and cerebrovascular impairment is well studied in able-bodied individuals. However, individuals with spinal cord injury (SCI) at or above the spinal segment T6 are prone to experience autonomic dysreflexia (AD) but als...
Autores principales: | Walter, Matthias, Ramirez, Andrea L, Lee, Amanda HX, Rapoport, Daniel, Kavanagh, Alex, Krassioukov, Andrei V |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252748/ https://www.ncbi.nlm.nih.gov/pubmed/30467135 http://dx.doi.org/10.1136/bmjopen-2018-024084 |
Ejemplares similares
-
Urodynamic efficacy of fesoterodine for the treatment of neurogenic detrusor overactivity and/or low compliance bladder
por: Kaga, Kanya, et al.
Publicado: (2020) -
Population Pharmacokinetic and Pharmacodynamic Modeling of Fesoterodine in Pediatric Patients with Neurogenic Detrusor Overactivity
por: Sano, Yamato, et al.
Publicado: (2023) -
Early Fesoterodine Fumarate Administration Prevents Neurogenic Detrusor Overactivity in a Spinal Cord Transected Rat Model
por: Biardeau, Xavier, et al.
Publicado: (2017) -
Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study
por: Wyndaele, J-J, et al.
Publicado: (2009) -
Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER
por: Kaplan, S A, et al.
Publicado: (2014)